Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis

被引:56
作者
Chu, Te-Wei
Yang, Jiyuan
Kopecek, Jindrich [1 ,2 ]
机构
[1] Univ Utah, Ctr Controlled Chem Delivery, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA
[2] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA
关键词
HPMA; CD20; Non-Hodgkin's lymphoma; Rituximab; B cell; Multivalency; MONOCLONAL-ANTIBODY; CROSS-LINKING; RITUXIMAB; POLYMERIZATION; MECHANISMS; THERAPIES; CELLS;
D O I
10.1016/j.biomaterials.2012.06.024
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
A hybrid biomimetic system comprising high-molecular-weight, linear copolymer of N-(2-hydroxypropyl)methacrylamide (HPMA) grafted with multiple Fab' fragments of anti-CD20 monoclonal antibody (mAb) was synthesized by reversible addition-fragmentation chain transfer (RAFT) polymerization followed by attachment of Fab' fragments via thioether bonds. Exposure of human non-Hodgkin's lymphoma (NHL) Raji B cells to the multivalent conjugates resulted in crosslinking of CD20 receptors and commencement of apoptosis. Five conjugates with varying molecular weight and valence (amount of Fab' per polymer chain) were synthesized. One of the copolymers contained enzyme degradable peptide sequences (GFLG) in the backbone. The multivalency led to higher avidity and apoptosis induction compared to unconjugated whole mAb. Time-dependent studies showed that the cytotoxicity of conjugates exhibited a slower onset at shorter exposure times than mAb hyper-crosslinked with a secondary Ab; however, at longer time intervals the HPMA copolymer conjugates achieved significantly higher biological efficacies. In addition, study of the relationship between the structure of conjugates and Raji B cell apoptosis revealed that both valency and polymer molecular weight influenced biological activities, while insertion of peptide sequences into the backbone was not a factor in vitro. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7174 / 7181
页数:8
相关论文
共 41 条
  • [1] A NEW STRATEGY FOR ATTACHMENT OF ANTIBODIES TO STERICALLY STABILIZED LIPOSOMES RESULTING IN EFFICIENT TARGETING TO CANCER-CELLS
    ALLEN, TM
    BRANDEIS, E
    HANSEN, CB
    KAO, GY
    ZALIPSKY, S
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1995, 1237 (02): : 99 - 108
  • [2] Allison M, 2001, NAT BIOTECHNOL, V28, P105
  • [3] Modifying the Body Distribution of HPMA-Based Copolymers by Molecular Weight and Aggregate Formation
    Allmeroth, Mareli
    Moderegger, Dorothea
    Biesalski, Barbara
    Koynov, Kaloian
    Roesch, Frank
    Thews, Oliver
    Zentel, Rudolf
    [J]. BIOMACROMOLECULES, 2011, 12 (07) : 2841 - 2849
  • [4] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
    Cartron, G
    Dacheux, L
    Salles, G
    Solal-Celigny, P
    Bardos, P
    Colombat, P
    Watier, H
    [J]. BLOOD, 2002, 99 (03) : 754 - 758
  • [5] Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
    Cheson, Bruce D.
    Leonard, John P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (06) : 613 - 626
  • [6] Nanotechnology: Intelligent design to treat complex disease
    Couvreur, Patrick
    Vauthier, Christine
    [J]. PHARMACEUTICAL RESEARCH, 2006, 23 (07) : 1417 - 1450
  • [7] In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
    de Haij, Simone
    Jansen, J. H. Marco
    Boross, Peter
    Beurskens, Frank J.
    Bakema, Jantine E.
    Bos, Desiree L.
    Martens, Anton
    Verbeek, J. Sjef
    Parren, Paul W. H. I.
    van de Winkel, Jan G. J.
    Leusen, Jeanette H. W.
    [J]. CANCER RESEARCH, 2010, 70 (08) : 3209 - 3217
  • [8] Self-association properties of HPMA copolymers containing an amphipathic heptapeptide
    Ding, Hui
    Kopeckova, Pavla
    Kopecek, Jindrich
    [J]. JOURNAL OF DRUG TARGETING, 2007, 15 (7-8) : 465 - 474
  • [9] TISSUE SULFHYDRYL GROUPS
    ELLMAN, GL
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1959, 82 (01) : 70 - 77
  • [10] Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin
    Ghetie, MA
    Bright, H
    Vitetta, ES
    [J]. BLOOD, 2001, 97 (05) : 1392 - 1398